Goldman Sachs’s Aerie Pharmaceuticals AERI Stock Holding History

Goldman Sachs’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-49,700	Closed	-$604K	–	7329
2016 Q1	$604K	Buy	49,700 +8,700	+21%	+$138K	﹤0.01%	4563
2015 Q4	$998K	Buy	41,000 +11,000	+37%	+$257K	﹤0.01%	4300
2015 Q3	$532K	Buy	+30,000	New	+$543K	﹤0.01%	5083
2015 Q2	–	Sell	-10,000	Closed	-$313K	–	7502
2015 Q1	$313K	Buy	+10,000	New	+$290K	﹤0.01%	5602

Goldman Sachs's AERI Position: Q4 2022 in Review

Goldman Sachs sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 939,811 shares — an estimated $14.2M sold.

Goldman Sachs first reported a position in AERI in Q2 2014 and held it in 34 quarters. The position peaked at $14.2M in Q3 2022. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.

Goldman Sachs reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Goldman Sachs sold 939,811 Aerie Pharmaceuticals shares in Q4 2022, an estimated $14.2M.
Goldman Sachs first reported a position in Aerie Pharmaceuticals in Q2 2014 and held it in 34 quarters.
Goldman Sachs's Aerie Pharmaceuticals position peaked at $14.2M in Q3 2022.
0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.

Based on Goldman Sachs's 13F filing for Q4 2022, filed 13 Feb 2023.